Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Lixivaptan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Centessa Pharma To No Longer Develop Lixivaptan For Treatment Of ADPKD
    Centessa Pharma To No Longer Develop Lixivaptan For Treatment Of ADPKD

    03 Jun 2022

    // NASDAQ

    https://www.nasdaq.com/articles/centessa-pharma-to-no-longer-develop-lixivaptan-for-treatment-of-adpkd

    NASDAQ
    03 Jun 2022
    Share Share
    Palladio Biosciences Announces First Patient Dosed The ALERT Study
    Palladio Biosciences Announces First Patient Dosed The ALERT Study

    17 Nov 2020

    // BIOSPACE

    https://www.biospace.com/article/releases/palladio-biosciences-announces-first-patient-dosed-with-lixivaptan-in-the-alert-study-a-phase-3-study-of-adpkd-patients-previously-discontinued-from-treatment-with-tolvaptan-due-to-liver-toxicity/

    BIOSPACE
    17 Nov 2020
    Share Share
    Palladio Announces First Patient Dosed With Lixivaptan in The ALERT Study
    Palladio Announces First Patient Dosed With Lixivaptan in The ALERT Study

    17 Nov 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201117005255/en

    BUSINESSWIRE
    17 Nov 2020
    Share Share
    Palladio Biosciences Announces Presentation of Data from a Study of Lixivaptan
    Palladio Biosciences Announces Presentation of Data from a Study of Lixivaptan

    20 Oct 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201020005214/en/Palladio-Biosciences-Announces-Presentation-of-Data-from-a-Study-of-Lixivaptan-Use-in-an-ADPKD-Patient-who-Previously-Experienced-Liver-Toxicity-with-Tolvaptan-During-the-American-Society-of-Nephrology-Kidney-Week-2020-Meeting

    BUSINESSWIRE
    20 Oct 2020
    Share Share
    Palladio Completes $20 Million Series B Financing
    Palladio Completes $20 Million Series B Financing

    25 Sep 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200925005062/en

    BUSINESSWIRE
    25 Sep 2020
    Share Share
    Palladio Biosciences Announces ELiSA Ph 2 Study Results and Phase 3 Lixivaptan
    Palladio Biosciences Announces ELiSA Ph 2 Study Results and Phase 3 Lixivaptan

    05 Nov 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20191105005459/en

    BUSINESSWIRE
    05 Nov 2019
    Share Share